Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor (DXR) announces expansion of its ezBVA Lab blood volume analysis service to two new health systems. The expansion includes an Arizona-based multi-campus medical center for outpatient nephrology care and a regional health network serving Southwest Iowa, Nebraska, Minnesota, and North Dakota for heart failure outpatient management.
The ezBVA Lab service provides cost-effective blood volume analysis with minimal initial investment and broad reimbursement coverage. The company reports this expansion contributes to their strongest quarter ever in terms of revenue and year-over-year growth.
Daxor (NASDAQ: DXR), the global leader in blood volume measurement technology, will be exhibiting at the MedAxiom Cardiovascular (CV) Transforum Fall'24 Conference from October 17-19, 2024, in Aurora, CO. This elite conference unites cardiovascular thought-leaders to transform care and introduce innovative solutions.
Daxor's CEO, Michael Feldschuh, emphasized the opportunity to showcase their BVA-100™ Blood Volume Diagnostic, which addresses key challenges in cardiovascular care. Peer-reviewed studies have shown that BVA-guided care significantly improves patient outcomes, including:
- 82% reduction in 30-day mortality
- 86% reduction in 1-year mortality
- 56% reduction in 30-day readmissions
- 57% reduction in length of stay when performed upon admission
The BVA technology provides 98% accurate, actionable data for optimizing treatment plans and individualizing care, ultimately improving outcomes while reducing duration and cost.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, announces its participation in the 2024 Maxim Healthcare Virtual Summit. CEO and President Michael Feldschuh will engage in a fireside chat with Maxim's Director of Research and Senior Healthcare Analyst Anthony Vendetti on Tuesday, October 15, 2024, at 10:00 AM ET.
The summit runs from October 15 – 17, 2024. Investors can access the fireside chat via webcast at https://m-vest.com/events/healthcare-10152024. Mr. Feldschuh will also be available for one-on-one meetings with registered summit investors. Interested parties can contact Bret Shapiro at CORE IR by calling 1-516-222-2560 or emailing brets@coreir.com to arrange meetings.
Daxor (NASDAQ: DXR), a leader in blood volume measurement technology, announces its participation in the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024. The event, scheduled for September 27-30 in Atlanta, will feature Daxor's Blood Volume Analysis (BVA) technology. Key highlights include:
1. Exclusive BVA showcase in the 'Devices in Heart Failure' session
2. Product presentation in the main Exhibit Hall
3. Corporate Member Meeting with HFSA leadership
Daxor's CEO emphasizes the importance of BVA in personalizing treatment and improving patient outcomes. BVA-guided treatment has shown significant reductions in heart failure readmissions, mortality rates, and hospital stays. Daxor will be exhibiting at Booth 225 during the conference.
Daxor (Nasdaq: DXR) announces a pivotal review published in Cardiorenal Medicine highlighting the important role of Blood Volume Analysis (BVA) in managing cardiorenal syndrome (CRS). The review, authored by expert contributors, emphasizes BVA's significance in enhancing the precision of diuretic and red cell therapies, leading to improved patient care and outcomes. Key findings include:
- BVA's 98% accuracy in measuring total blood and red blood cell volumes
- BVA's potential to optimize personalized therapy for CRS patients
- Projected growth of CRS patient population to 47 million by 2030
Daxor's CEO, Michael Feldschuh, emphasizes BVA technology's potential to improve outcomes while reducing care duration and costs in CRS management.
Daxor (NASDAQ: DXR), a leader in blood volume measurement technology, has been awarded a $300,000 SBIR matching fund by Launch Tennessee (LaunchTN). This funding will support the development of Daxor's next-generation point-of-care blood volume analyzer, building on their Phase II award from the Defense Health Agency. The award underscores Daxor's commitment to innovation, job creation, and its presence in Oak Ridge, Tennessee.
CEO Michael Feldschuh highlighted the importance of this non-dilutive funding in empowering clinicians with advanced tools for optimal fluid management and enhancing patient outcomes. LaunchTN, a public-private partnership, aims to foster entrepreneurship and economic development in Tennessee through various support mechanisms.
Daxor (Nasdaq: DXR) has announced the expansion of its blood volume analysis (BVA) capabilities through its ezBVA Lab service. The company is partnering with a leading 1,000+ bed comprehensive medical center in western Florida to provide lab processing of patient tests, offering a rapid 24-hour testing service. This implementation aims to optimize heart failure treatment outcomes, improve patient and clinical experiences, and reduce associated costs.
The BVA-100™ Blood Volume Diagnostic facilitates optimal diagnosis of patient volume status, which is important for both in-patient and out-patient heart failure care. Daxor's CEO, Michael Feldschuh, emphasized that their BVA diagnostic delivers 98% accurate, actionable data to guide individualized fluid management, enhancing patient outcomes and optimizing costs. The ezBVA Lab service is reimbursed by both public and private insurance in inpatient and outpatient care using established CPT codes.
Daxor (Nasdaq: DXR), a leader in blood volume measurement technology, reported significant growth in its mid-year update for 2024. Key highlights include:
1. Net Asset Value (NAV) increased to $6.75 per share from $6.33 last year.
2. Unaudited revenue for the first half of 2024 more than doubled compared to 2023.
3. Added 14 new accounts, surpassing the 12 added in 2023.
4. Reduced net cash investment to $1.297 million from $2.445 million in H1 2023.
5. Secured $2.45 million in government contracts for technology development.
6. Acquired Volumex®, Megatope®, and Glofil® to improve margins and expand product offerings.
7. Expecting operational positive cash flow by Q4 2024.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024 at the Lotte New York Palace Hotel in New York City.
CEO and President Michael Feldschuh will deliver a presentation, which will be available on-demand starting September 9, 2024, at 7:00 AM ET. Investors can register for the conference to access the presentation. Additionally, Mr. Feldschuh will be available for one-on-one meetings with registered investors at the conference venue.
Interested investors can contact Bret Shapiro at CORE IR by calling 1-516-222-2560 or emailing brets@coreir.com for more information or to schedule meetings.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has announced the expansion of its Blood Volume Analysis (BVA) technology. A 339-bed community hospital in northwest Mississippi, part of the Mid-South's largest integrated delivery network, has acquired a BVA analyzer for outpatient heart failure care. This acquisition is expected to enhance patient outcomes in a region with access to specialized care and accelerate sales growth for Daxor.
The move is particularly significant given Mississippi's high heart disease death rate of 324.4 per 100,000 people, compared to the national average of 173.8. Daxor's BVA diagnostic provides 98% accurate actionable data to guide fluid management decisions, enabling personalized care plans for heart failure patients. This technology is important for proactive management, early intervention, and continuous monitoring, which can help prevent hospitalizations and reduce healthcare costs.
FAQ
What is the current stock price of Daxor Corporation (DXR)?
What is the market cap of Daxor Corporation (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
